gshc2020.com

It's not all as simple as east vs west, however, as much of China's hardware is still, in fact, bought from the Western company ASML. The Financial Times reports that, "according to a person with knowledge of the matter", [Chinese memory makers] CXMT and YMTC have managed to stock up on enough DUV machines from western machine-maker ASML to support their next three years of expansion plans.

This is despite the push—not just from the Chinese government but also from companies such as Huawei, as the FT also reports—to back domestic production and eliminate foreign tech from China. Domestic alternatives are still said to be a few years behind ASML machines' productivity levels.

Deep ultraviolet (DUV) machines aren't the latest and greatest ones—extreme ultraviolet (EUV) ones are—but they're still what a lot of chipmakers, even in the West, still use. It's recently been confirmed that Samsung and TSMC will be moving to high numerical aperture (high-NA) EUV production by 2028 and 2030, respectively, and these two already use low-NA EUV, but the older DUV tech is still very widely used for chip production even by these companies.

There's been a rumour for some time that China has its hands on an EUV machine, and there have even been concerns that the country might have its hands on one made by ASML despite the newer tech being banned for sale and export to China, though the Dutch machine maker denies this.

At any rate, even without EUV capabilities, China can still play a mighty quick catch-up with DUV. CXMT and YMTC having three years' worth of machines for their planned chipmaking expansion will certainly help. China is reportedly making its own DUV machines, but buying some ready-made from ASML will do the job.

The former company has been quickly and steadily increasing its market share of late, and while its memory is still almost solely ending up in domestic products, that's not guaranteed to always be the case. Plus, Chinese customers keeping away from Western memory still puts competitive pressure on Western memory makers and manufacturers.

The PC Gamer Circuit Breaker newsletter breaks down the latest PC gaming tech, and finds you the best deals on the best products

CXMT's memory has even started to adorn RAM kits that match our preferred specs for gaming PCs here in the West, which gives us a particularly concrete idea of how far the Chinese memory industry has come. And with plans for ever-more fabrication plants, it's all to play for.

Jacob got his hands on a gaming PC for the first time when he was about 12 years old. He swiftly realised the local PC repair store had ripped him off with his build and vowed never to let another soul build his rig again. With this vow, Jacob the hardware junkie was born. Since then, Jacob's led a double-life as part-hardware geek, part-philosophy nerd, first working as a Hardware Writer for PCGamesN in 2020, then working towards a PhD in Philosophy for a few years while freelancing on the side for sites such as TechRadar, Pocket-lint, and yours truly, PC Gamer. Eventually, he gave up the ruthless mercenary life to join the world's #1 PC Gaming site full-time. It's definitely not an ego thing, he assures us. %!s()

On Instagram on Tuesday, the 86-year-old said he has been let go as a judge and criticized the limited role he was offered instead. “To be clear, I did not want to leave The Voice as I love the show and really appreciate the audience,” he wrote. “ITV made this decision — obviously a while ago, and I was told just recently. The reason given is because of a financial difficulty with insurance.”

“They now say in the press they wanted to ‘refresh’ the show, and with a new coaching line-up there wouldn’t be a chair for me,” he continued. “They are offering a much-reduced role where I would make an appearance but without being actually involved from the start, and I’m not thrilled about that. So the only thing I know right now, is that there’s never a good time to fire an 86-year-old who’s still pretty good at his job.”

ITV has corroborated Jones’ leaving the show, telling THR on Tuesday: “We have loved working with Sir Tom Jones over the past nine years on The Voice UK. While he will no longer be a full-time coach on series 15, we continue to talk to Sir Tom and his team about his involvement in the next series.”

Jones’ post immediately earned hundreds of comments of support, including from English singers Olly Murs and Anne-Marie and fellow Voice coach Will.i.am.

“Love ya TJ,” said Murs. “I know how much that show means to you mate. Absolute legend and one of the very best to ever sit in that chair.” U.K. presenter Carol Vorderman wrote under the post: “Terrible decision [in my honest opinion]… I saw you perform at Car Fest and you remain simply incredible and A LEGEND. You ARE The Voice.”

Jones is currently appearing on season nine (at ITV) of The Voice U.K., in which amateur singers — some of whom are incredibly talented — perform while the judges’ backs are turned. Those who are successful are coached through to the final. Jones has won the show three times with his mentees.

His fellow coaches include McFly members Tom Fletcher and Danny Jones as well as Kelly Rowland. %!s()

While I'm leaning into the physical: strength, vitality, movement, health, feeling capable and energized in my body, my partner leans into the mental: curiosity, learning, ideas, creativity, reflection, exploring new thoughts, understanding the world and herself more deeply.

Our interests complement each other

I don't see our preferences as opposites — they're complements. One fuels the body that carries you through life; the other fuels the mind that gives it meaning. Both are forms of growth, and both are deeply valuable.

We celebrate each other's wins instead of comparing, cheer each other on, and learn from each other's worlds. I tell her how much I admire her curiosity and love of learning, and ask questions so she can share. She lets me know how good it feels to see me strong, lean, and active.

In my spare time, I focus on maintaining my weight and challenging myself at the gym three times a week. I get on my mountain bike or hike up mountains. I tell my partner what I've been doing in my workouts, and we make a point of walking together every day, even in the rain.

My partner enjoys expanding her knowledge of health, therapies, and natural remedies. Like me, she likes to hike or bike ride, but not as often. Fortunately, we can each pursue our individual interests, grow and learn from each other, and come together to share experiences as we grow older.

We still spend a lot of time together sharing our interests

Common goals and roles still apply in our relationship, and we still spend much of our spare time together, incorporating our interests. I recently joined her on a keto diet and lost eight pounds, and I've tried Pilates, high-intensity interval training, and meditation in recent months. I've also enjoyed letting my partner practice and refine some of her therapy techniques on me over the years. Whether it's using Reiki for relaxation, the Bowen Technique to relieve pain and stress, or an herbal remedy for joint pain or digestive issues, these natural health therapies benefit us both.

We also love sharing gardening and cooking duties. We enjoy camping, traveling, and taking an active interest in what our 21-year-old daughter is up to. We also recognize and respect each other's space more these days, and the importance of solo time; our time together is growing, and it has more intent than when we were working full time.

I feel that growing stronger physically and having better stamina makes me more capable and makes me feel alive and ready for everything I tackle. My partner's exploration of ideas and understanding of the world excites her and makes both our lives more meaningful and richer.

We see each other's individual interests as shared love expressed differently, which means there's no tension — only admiration. That's partnership at its finest: same destination, two beautiful ways of walking it.

After six decades on planet Earth, we both realize that a healthy life is built on a foundation where body and mind thrive together. I've got the body covered; my partner's got the mind covered. And together, we've got life and our relationship covered.

Read next

• Health

Younger readers might not remember a time when Call of Duty wasn't one of the biggest franchises in all of gaming, but I promise you that there was a time. I had played the original on PC — the only platform it had been released on — back in 2003. And, yes, I quite liked it. It was an excellent World War 2-set military first-person shooter.

When it came time for the sequel in 2005, which was slated to be a day-one launch title for the then-upcoming Xbox 360 console, my Official Xbox Magazine colleagues and I were excited about it, but it wasn't necessarily the most anticipated Xbox 360 launch game. (In hindsight, nothing really was; while the original Xbox had a killer app in Halo: Combat Evolved, it had little else in its launch lineup, whereas the Xbox 360 had a few excellent games — like Project Gotham Racing 3, Condemned: Criminal Origins, and of course Call of Duty 2 — but no Halo-level must-haves.)

My eager but not feverish anticipation for Call of Duty 2 changed when I got to go to Infinity Ward in the summer of 2005 to do a cover story on Infinity Ward's sequel. And I remember very clearly what jumped out at my first as I was shown an early mission from the campaign: the volumetric smoke effects. With the increased horsepower of the Xbox 360, smoke grenades mattered more than ever during gameplay, as tossing them to obscure the enemy's vision while you darted across the path nearby Axis a-holes was integrated into the mission design.

With the increased horsepower of the Xbox 360, smoke grenades mattered more than ever during gameplay.“

It was a really fun way to work the Xbox 360's new tricks into the action. Couple that with the excellent sound effects and surround-sound audio work the Xbox had baked in (in fairness, the original Xbox was also fully 5.1-capable) and I suddenly found myself looking forward to Call of Duty 2 more than any other game in the 360's rather large launch lineup.

Fast-forward to the fall of that year and the imminent launch of the new Xbox. As I've mentioned before in some of my other Xbox 25th anniversary look-backs at my favorite games from the platform's past, magazines are made well in advance in order to allow time for printing and shipping to our hundreds of thousands of subscribers. This meant that we typically got access to review builds of games well in advance (think: two months). This was usually no problem for developers to provide, as the submission builds they'd submit to the Xbox certification team were typically pretty final; the age of day-one patches had not yet dawned.

But in this case, I had to go to the game, rather than the other way around, as security was tight around both the new Xbox and the new Call of Duty. And so I returned to Infinity Ward in southern California to spend a few days reviewing Call of Duty 2. I began with campaign before moving to multiplayer (against the Infinity Ward QA testers and multiplayer team, who had the distinct advantage of having played dozens if not hundreds of hours of multiplayer compared to my zero hours). Remember earlier when I said I quite enjoyed the original Call of Duty on PC? Call of Duty 2's campaign on Xbox 360 was significantly better. More action, more drama, more tension. It was wildly impressive by any metric, which was especially important considering that Call of Duty multiplayer had not yet established itself as the main reason many people bought each new game.

Make no mistake, though: multiplayer was awesome. Multiple game modes, a short TTK (remember, it was all pretty new at the time!), killer graphics, and don't forget it was the pre-Party Chat era when most people actually used the Chat Headset bundled with every Xbox 360 and communicated with their teammates. Looking back, it was the beginning of the end of Halo's reign as the king of console shooters. Halo 2 was absolutely still being played by a ton of people after the Xbox 360 launched (as you may recall, Halo 1 and 2 were the first two backwards compatible games with Xbox 360, and that compatibility was baked into the new console out of the box), and Halo 3 would have its moment two years later...right before Infinity Ward's next project, Call of Duty 4: Modern Warfare, took the crown from Halo for good.

Call of Duty 2 was, quite simply, the right game at the right time for Xbox 360. It showed gamers what the new console was capable of while also being a stellar game regardless of platform. It probably wouldn't hold up today, honestly, but if you had the pleasure of being there at the time, it was a heck of a moment in the history of Xbox.

Ryan McCaffrey is IGN's executive editor of previews and host of IGN's weekly Xbox show, Podcast Unlocked, and a co-host of Next-Gen Console Watch. He's a North Jersey guy, so it's "Taylor ham," not "pork roll." Debate it with him on Twitter at @DMC_Ryan. %!s()

"Patients pay the tariff," Sandoz CEO Richard Saynor said in an interview with CNBC during its Capital Markets Day.

"Any business is not going to systematically continue to supply a product at a material loss," he said on Tuesday. "So you either then have a choice of putting the price [up] or not supplying the product."

Trump said in July that imported generic medicines could face tariffs of 100% from 2028, rising to as much as 200% a year later, as his administration seeks to encourage drugmakers to shift pharmaceutical manufacturing to the United States.

Generics are currently exempt from the administration's Section 232 pharmaceutical tariffs. CNBC has contacted the White House for comment.

Brand-name drugmakers typically spend years developing costly new medicines that, once approved, benefit from exclusivity that allows them to sell those drugs without direct competition for a limited period of time. By contrast, generic drug manufacturers like Sandoz enter the market after patents expire and often compete on price, manufacturing efficiency and scale against other companies selling largely identical versions of the same medicine.

Generic medicines account for about 90% of prescriptions in the U.S., but a relatively small share of overall drug spending due to their lower prices.

Saynor reiterated that around nine in 10 prescriptions dispensed in the U.S. are for generics and biosimilars, while much of the underlying drug substance is produced outside the country.

Sandoz, one of the world's largest makers of off-patent medicines, generates roughly a quarter of its revenue in North America, including Canada.

Sandoz share price

The CEO's comments come as Sandoz announced a new drive to capitalize on what it sees as an unprecedented wave of patent expirations and loss of exclusivity for branded medicines, creating opportunities for new generic and biosimilar competition, particularly in immunology and oncology.

Its Swiss-listed shares rose as much as 5% on Tuesday, before paring gains and trading about 1% lower in afternoon trading.

Multibillion-dollar opportunity

The company said it aims to more than double net sales by 2035 and increase its core profit margin to above 30%. Jefferies analysts noted that the revenue ambition sits about 13% above current consensus for 2035.

Sandoz also said it wanted to expand in biosimilars to more than 100 products by 2040, up from 13 currently.

RBC analysts called the targets mixed and said the mid-term targets for 2030 look "light."

"That said, the 2035 targets are more ambitious and show an expected acceleration through the early 2030s, a rich period for new biosimilar launches," the analysts added.

Weight-loss and diabetes GLP-1 drugs represent additional upside that is currently not included in the 2035 sales target, the company said. Asked by CNBC to quantify the opportunity, Saynor said Sandoz's GLP-1 business could bring in "billions of dollars, but I have no idea how many billions of dollars," citing the market's still early days.

Sandoz secured approval in Brazil earlier this year to launch generic semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, and expects Canadian approval soon. Key U.S. and European markets will not lose exclusivity until early next decade.

While generic drugs are lower-cost versions of conventional medicines whose patents have expired, biosimilars are highly similar alternatives to more complex biologic medicines. Sandoz plans to target around 80% of the value of biologic drugs losing patent protection from 2035, up from about 50% today.

Because biosimilars are more complex, Saynor sees fewer competitors in the space.

"There still remains a complex space requiring capital, scale, and technical expertise. The players that can do this are few and far between, and given the sheer scale and number of [loss of exclusivities] ahead, competitive intensity at asset level is expected to reduce," he said.

Sandoz became an independent company in 2023 after Swiss pharmaceutical giant Novartis spun off its generics and biosimilars business to focus solely on branded medicines. Saynor has led the business since 2019. %!s()